The Rise of Synaptic Density PET Imaging
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Many neurological disorders are related to synaptic loss or pathologies. Before the boom of positrons emission tomography (PET) imaging of synapses, synaptic quantification could only be achieved in vitro on brain samples after autopsy or surgical resections. Until the mid-2010s, electron microscopy and immunohistochemical labelling of synaptic proteins were the gold-standard methods for such analyses. Over the last decade, several PET radiotracers for the synaptic vesicle 2A protein have been developed to achieve in vivo synapses visualization and quantification. Different strategies were used, namely radiolabelling with either 11C or 18F, preclinical development in rodent and non-human primates, and binding quantification with different kinetic modelling methods. This review provides an overview of these PET tracers and underlines their perspectives and limitations by focusing on radiochemical aspects, as well as preclinical proof-of-concept and the main clinical outcomes described so far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“of SV2A being the binding site of the first-in-class antiepileptic drug levetiracetam is one of these significant steps [1].”
BackgroundHippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017 · cited 2×
“Besides the obvious importance of SV2A in epilepsy, AD is a perfect illustration of the clinical interest of synaptic density quantification [7,8].”
BackgroundSanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575 · cited 2×
“UCB-J in vivo quantification in human brain was presented in the publication of Finnema 2016 where the authors proposed the CS as a reference region for non-displaceable binding [40].”
BackgroundMethodLower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484
Chen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431 · cited 1×
“The first study reporting SV2A PET assessment in AD was published by the University of Yale and used UCB-J [57].”
MethodAbnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 1×
“The protein is ubiquitously expressed throughout the brain and is known to be essential for proper brain development and functioning [2,3].”
BackgroundNabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296 · cited 5×
“The UCB-J was initially developed in rhesus monkey [24].”
BackgroundMethodInfluentialOnwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14122-0 · Cited by 243 · cited 1×
“Concerning psychiatric disorders, a recent article reported the in vivo investigation of synaptic density in schizophrenia [62].”
BackgroundNicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia · doi:10.1111/epi.13267 · Cited by 169 · cited 1×
“They used PET imaging to prove a faster SV2A occupancy by brivaracetam compared with levetiracetam [42].”
MethodAssessment of a white matter reference region for 11 C-UCB-J PET quantification
Rossano, S., Toyonaga, T., Finnema, S. J., Naganawa, M., Lu, Y., Nabulsi, N., Ropchan, J., De Bruyn, S., Otoul, C., Stockis, A., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19879230 · Cited by 126 · cited 3×
“In a recent study aiming at the validation of the CS, Rossano et al. investigated the region of interest definition and the reconstruction parameters (number of iteration of the ordered subset expectation minimization “OS-EM” [53].”
BackgroundInfluentialKoole, M., van Aalst, J., Devrome, M., Mertens, N., Serdons, K., Lacroix, B., Mercier, J., Sciberras, D., Maguire, P., & Van Laere, K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4119-8 · Cited by 118
Evaluation of18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85 · cited 4×
“Afterward, preclinical investigations with UCB-H were conducted in rats (Sprague Dawley) considering that their size better suits microPET brain imaging, as well as images quantification with invasive protocols [19].”
BackgroundMethodSelf-citationToyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223867 · Cited by 79 · cited 1×
“Recently, UCB-J was investigated in mice and more specifically in the amyloid precursor protein and presenilin 1 double-transgenic (APPswe/PS1DE9 [APP/PS1]) mouse model of Alzheimer disease [41].”
Background[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A
Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.004 · Cited by 71
Finnema, S. J., Rossano, S., Naganawa, M., Henry, S., Gao, H., Pracitto, R., Maguire, R. P., Mercier, J., Kervyn, S., Nicolas, J., et al. (2019) · Epilepsia · doi:10.1111/epi.14701 · Cited by 65 · cited 1×
“As a logical follow-up of the preclinical study that supported the development of the brivaracetam anti-epileptic drug, UCB Pharma and Yale University released a drug occupancy study in human for brivaracetam using [11C]UCB-J PET [59].”
MethodMeasuring brain synaptic vesicle protein 2A with positron emission tomography and [ 18 F]UCB‐H
Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61 · cited 4×
“The input function was derived from dynamic PET images [43].”
MethodSelf-citationLi, S., Cai, Z., Zhang, W., Holden, D., Lin, S.-F., Finnema, S. J., Shirali, A., Ropchan, J., Carre, S., Mercier, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04357-w · Cited by 59
Warnier, C., Lemaire, C., Becker, G., Zaragoza, G., Giacomelli, F., Aerts, J., Otabashi, M., Bahri, M. A., Mercier, J., Plenevaux, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00905 · Cited by 58
Self-citationRadiosynthesis of 11C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression
Cai, H., Mangner, T. J., Muzik, O., Wang, M.-W., Chugani, D. C., & Chugani, H. T. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500285t · Cited by 58
Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H
Bretin, F., Warnock, G., Bahri, M. A., Aerts, J., Mestdagh, N., Buchanan, T., Valade, A., Mievis, F., Giacomelli, F., Lemaire, C., et al. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-35 · Cited by 43 · cited 1×
“The first in vivo description of SV2A PET radiotracer has been achieved in mice with UCB-H for dosimetric analysis purpose [36].”
BackgroundSelf-citationPharmacokinetic Characterization of [18F]UCB-H PET Radiopharmaceutical in the Rat Brain
Becker, G., Warnier, C., Serrano, M. E., Bahri, M. A., Mercier, J., Lemaire, C., Salmon, E., Luxen, A., & Plenevaux, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00235 · Cited by 31 · cited 4×
“The first step for a non-invasive quantification of UCB-H in rat brain used a population-based input function (PBIF) [37].”
MethodInfluentialSelf-citation
Cited by
Synaptic plasticity and mental health: methods, challenges and opportunities
Appelbaum, L. G., Shenasa, M. A., Stolz, L., & Daskalakis, Z. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01370-w · Cited by 240
Vanderlinden, G., Ceccarini, J., Vande Casteele, T., Michiels, L., Lemmens, R., Triau, E., Serdons, K., Tournoy, J., Koole, M., Vandenbulcke, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01672-x · Cited by 47
“Whereas previously NFTs and synaptic loss needed to be assessed postmortem or ex vivo, the development of novel imaging biomarkers over the recent years has allowed an in vivo quantitative and regional assessment of both p-τ as well as synaptic density in the living brain [9, 10].”
BackgroundVisser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
Corvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03369-3 · Cited by 1
Metadata
- Authors
- Becker, G., Dammicco, S., Bahri, M. A., & Salmon, E.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-05-14
- Volume
- 25
- Issue
- 10
- Pages
- 2303
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3025287530
- Cited by
- 31
- References
- 22
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.